This appointment will provide additional coverage focused on the northeast US region which is home to many leading healthcare providers and medical technology pioneers.  Q-linea has made four new hires into its US commercial team in recent months following FDA approval of its flagship ASTar rapid AST system.
 
“We are very excited to be building a team of experienced industry leaders who can help to bring our novel technology to laboratories and patients across the US.  We have seen a notable increase in our pipeline of interested customers since FDA clearance in April and this additional resource will facilitate our aim to place our first commercial ASTar instruments in the US during Q4 2024 and continue to deliver on our plan during the first half of 2025”, says Jim Kathrein, VP US Commercial Operations.
 
Q-linea is a market leader in rapid antimicrobial susceptibility testing (rAST) and received FDA approval in April 2024 for its blood culture Gram-negative panel on the ASTar diagnostic instrument.  It is to date the only rAST platform to receive dedicated New Technology Add-on Payment (NTAP) reimbursement funding from the US CMS.